Valuation: Phathom Pharmaceuticals, Inc.

Market Cap 558M 498M 461M 417M 785M 52.69B 795M 5.52B 2.17B 27.7B 2.09B 2.05B 88.26B P/E 2026 *
-8.87x
P/E 2027 * 10.5x
Enterprise Value 561M 500M 463M 419M 789M 52.92B 798M 5.55B 2.18B 27.82B 2.1B 2.06B 88.64B EV / Sales 2026 *
1.78x
EV / Sales 2027 * 0.98x
Free-Float
94.83%
Yield 2026 *
-
Yield 2027 * -
1 day-3.83%
1 week-5.00%
Current month-3.70%
1 month-5.64%
3 months-37.51%
6 months-45.42%
Current year-57.63%
1 week 6.78
Extreme 6.78
7.57
1 month 6.52
Extreme 6.52
7.82
Current year 6.52
Extreme 6.52
18.09
1 year 6.52
Extreme 6.52
18.31
3 years 2.21
Extreme 2.21
19.71
5 years 2.21
Extreme 2.21
31.53
10 years 2.21
Extreme 2.21
64.54
Manager TitleAgeSince
Chief Executive Officer 61 2025-03-31
Director of Finance/CFO 66 2025-10-05
Compliance Officer - 2025-05-31
Director TitleAgeSince
Chairman 66 2022-01-31
Director/Board Member 71 2019-09-26
Director/Board Member 54 2019-11-30
Date Insider Type Main position Quantity % Market Cap. Importance
10/6/26 Tax

Chief Financial Officer

-13,485 0.0167%
9/3/26 Tax

Controller/Auditor

-460 0.0006%
7/14/26 Tax

Controller/Auditor

-1,555 0.0019%
Change 5-day change 1-year change 3-year change Capi.($)
-3.83%-5.00%-49.79%-24.08% 558M
-1.01%+5.13%+58.93%+117.36% 1,133B
-0.61%+1.52%+34.34%+68.48% 621B
-1.48%+0.47%+23.08%+94.76% 503B
-0.61%+2.61%+38.89%+64.01% 379B
+1.07%+1.70%+71.06%+45.98% 370B
+0.72%+1.56%+21.93%+51.31% 292B
+0.71%-0.14%+1.12%+25.54% 262B
-0.14%+2.87%+45.56%+57.22% 237B
-1.88%+0.02%+23.77%+97.39% 190B
Average -0.28%+2.39%+26.89%+59.80% 398.85B
Weighted average by Cap. +0.38%+3.73%+40.80%+79.79%

Financials

2026 *2027 *
Net sales 315M 281M 260M 235M 443M 29.75B 449M 3.12B 1.22B 15.64B 1.18B 1.16B 49.83B 489M 436M 404M 365M 688M 46.18B 697M 4.84B 1.9B 24.27B 1.84B 1.8B 77.35B
Net income -65.72M -58.56M -54.22M -49.07M -92.44M -6.2B -93.54M -650M -255M -3.26B -247M -241M -10.39B 52.48M 46.76M 43.3M 39.18M 73.82M 4.95B 74.69M 519M 204M 2.6B 197M 193M 8.29B
Net Debt 2.43M 2.16M 2M 1.81M 3.41M 229M 3.45M 24.01M 9.42M 120M 9.1M 8.91M 384M -77.63M -69.17M -64.04M -57.96M -109M -7.33B -110M -768M -301M -3.85B -291M -285M -12.27B
Projected Income Statement - Annual - Phathom Pharmaceuticals, Inc.
Logo Phathom Pharmaceuticals, Inc.
Phathom Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the commercialization and development of novel treatments for gastrointestinal diseases. It has in-licensed the exclusive rights to vonoprazan, a first-in-class potassium-competitive acid blocker (PCAB) for the United States (U.S.), Europe and Canada. PCABs are a novel class of molecules that block acid secretion in the stomach. The Company markets vonoprazan in the U.S. as VOQUEZNA (vonoprazan) tablets for the relief of heartburn associated with non-erosive gastroesophageal reflux disease (Non-Erosive GERD) in adults, the healing and maintenance of healing of Erosive GERD in adults and relief of associated heartburn, and as part of VOQUEZNA DUAL PAK (vonoprazan tablets, amoxicillin capsules) and VOQUEZNA TRIPLE PAK (vonoprazan tablets, amoxicillin capsules, clarithromycin tablets) for the treatment of H. pylori infection in adults.
Employees
371
Date Price Change Volume
26-10-21 US$7.030 -3.83% 784,175
26-10-20 US$7.310 +4.28% 724,324
26-10-19 US$7.010 +1.30% 1,017,111
26-10-16 US$6.920 -7.73% 1,254,290
26-10-15 US$7.500 +1.35% 1,210,198
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
MarketScreener Ratings - Phathom Pharmaceuticals, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
12
Last Close Price
7.030USD
Average target price
19.64USD
Spread / Average Target
+179.32%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Phathom Pharmaceuticals, Inc.
  1. Stock Market
  2. Stocks
  3. PHAT Stock